["{\"step_by_step_thinking\": \"The question asks to identify the scenario in which anti-D prophylaxis is not administered. From the provided documents, it can be inferred that anti-D immunoglobulin (RhoGAM) therapy is used to prevent Rh-hemolytic disease and Rh sensitization after delivery of an Rh-positive child. The documents do not mention any specific scenarios such as MTP at 63 days, amniocentesis at 16 weeks, manual removal of placenta, or intra-uterine transfusion at 28 weeks. Therefore, it is reasonable to conclude that anti-D prophylaxis is administered in all these scenarios except one.\", \"answer_choice\": \"A\"}"]